🧬 BioMed Pulse · 2026-10-22 02:01 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses, and New Cures

Thursday, October 22, 2026 | Edition #366

⚡ TL;DR

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has now recorded a confirmed imported case in Kenya, marking the first documented spread of this historic outbreak beyond the DRC-Uganda corridor and signaling a dangerous new geographic chapter.

Overall mood: Elevated concern across multiple fronts — an Ebola outbreak still the largest ever recorded in DRC history, a mysterious pneumonia death at a Russian biosecurity institute under investigation, and MERS-CoV cases continuing to emerge in Saudi Arabia.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC AND REGIONAL SPREAD

  • On 5 October 2026, WHO confirmed a laboratory-positive imported case of Bundibugyo virus disease in Kenya in a patient with recent travel history from DRC, transiting through Uganda. [1]
  • As of 11 September 2026, the DRC outbreak had expanded to 61 affected health zones spanning six provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo. [2]
  • A further two health zones were added after 11 September, including Bulu in a newly affected province, Sud Ubangi, in the DRC's northwest — indicating the outbreak is now pressing toward the country's western borders. [3]
  • WHO's Disease Outbreak News DON-619 characterizes this as the largest Ebola outbreak ever recorded in the DRC and describes transmission as ongoing and sustained. [4][5]
  • The outbreak was first identified on 5 May 2026 in Mongbwalu Health Zone, Ituri Province, following high-mortality illness and health worker deaths; Bundibugyo virus was confirmed by the Institut national de recherche biomédicale on 14 May 2026. [6]

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIAN FEDERATION

  • On 2 October 2026, WHO became aware via media reports of the death of an employee at the Irkutsk Antiplague Research Institute (APRI) of Siberia and the Far East, Russian Federation, who died of severe pneumonia. [7]
  • The pathogen and precise exposure route remain undetermined; WHO has designated this a Disease Outbreak News event (DON-620) and is seeking additional information from Russian health authorities. [7]
  • Given the victim's workplace at a facility that handles dangerous pathogens, the event is under close international scrutiny pending further laboratory findings. [7]

MERS-CoV — KINGDOM OF SAUDI ARABIA

  • Between 1 January and 5 October 2026, Saudi Arabia reported eight laboratory-confirmed cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), including one death. [8]
  • Cases were detected across six locations: Al Jouf, Arar, Hafr Al-Batin, Riyadh (two cases), Tabuk, and additional sites. [8]
  • WHO's Disease Outbreak News (DON-620 series) continues to monitor camel-to-human and limited human-to-human transmission patterns consistent with prior MERS seasonality. [8]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP

  • WHO's fifth Disease Outbreak News (DON-611) on the Andes hantavirus (ANDV) outbreak linked to cruise ship M/V Hondius, first notified to WHO on 2 May 2026, was published 2 July 2026 documenting ongoing multi-location case follow-up involving severe acute respiratory illness. [9]
  • The hantavirus outbreak spans multiple national locations, consistent with the international passenger manifest of the M/V Hondius; CDC issued multiple daily response transcripts throughout May and June 2026. [10]

NIPAH VIRUS — INDIA

  • On 11 June 2026, Kerala State Health Department confirmed one laboratory-confirmed case of Nipah virus (NiV) infection in a male adult in Kozhikode district, Kerala; the patient developed neurological symptoms on 30 May 2026 and was hospitalized on 10 June.
  • WHO DON-609 flagged this as a sporadic case consistent with Kerala's historical NiV cluster pattern, with contact tracing underway.

YELLOW FEVER — GLOBAL

  • From 1 January to 26 May 2026, six countries reported a total of 79 human yellow fever infections; transmission activity persisted into 2026 following an increase of cases across the Americas in 2025.
  • WHO DON-610 underscores the ongoing risk from Aedes and Haemagogus mosquito vectors in endemic zones across Africa and the Americas.

🧬 LONGEVITY & AGING

FERROPTOSIS AND DISC AGING

  • A study published in Bioactive Materials describes an iron-chelating, senescent-cell-targeted therapy designed to reprogram NOX4-associated "ferro-aging" — a process where iron-driven oxidative stress accelerates cellular senescence in intervertebral disc cells — aiming to treat disc degeneration.
  • NOX4 is an enzyme that generates reactive oxygen species; abnormal iron accumulation activates NOX4, pushing disc cells into a senescent, non-functional state — making iron chelation a novel anti-aging strategy for spinal health.

mTORC1 SILENCING FOR DISC DEGENERATION

  • Researchers at Kobe University and collaborators published in Bioactive Materials a cationized gelatin nanosphere system that delivers RNA interference targeting mTORC1, a central nutrient-sensing complex linked to cellular aging and autophagy suppression, to protect against intervertebral disc degeneration.
  • The controlled-release system demonstrated local silencing of mTORC1 signaling, preserving disc cell viability and matrix integrity in preclinical models.

AI FACE PHOTOGRAPHS AS BIOLOGICAL AGE ESTIMATORS

  • A model development and validation study published in Lancet Digital Health (Haugg F, Lee G et al., including researchers from the Gladyshev lab at Harvard and Brigham and Women's Hospital) describes FAHR-Face, a foundation AI model that estimates biological age and health status from standard face photographs.
  • The model was trained and validated across diverse populations, suggesting facial morphology encodes measurable aging signals that could serve as a low-cost longevity biomarker tool.

SINGLE-CELL HYDROGEL FOR AGED BONE REGENERATION

  • A Biomaterials study (Gu HY et al.) used single-cell transcriptomics to design a cascade-responsive hydrogel incorporating a bioinspired nanocellular pacemaker specifically engineered to overcome the diminished regenerative capacity of aged bone tissue.
  • The approach targets the aged bone microenvironment at the transcriptomic level, reprogramming cellular signaling cascades that stall regeneration in older patients.

SENESCENCE AFTER SPINAL CORD INJURY

  • Research published in Genes and Disease identified Glis1, a transcription factor, as a regulator of metabolic reprogramming via H3K18 lactylation — a histone modification driven by lactate metabolism — that can reduce neuronal senescence following spinal cord injury.
  • The study points to lactate-mediated epigenetic reprogramming as a potential target for preventing post-injury neurological aging.

OSTEOARTHRITIS CARTILAGE REPAIR

  • A Bioactive Materials study (Yu H, Hu Z et al.) developed a DNA-adsorbing nanozyme hydrogel that reprograms the immuno-oxidative microenvironment to support stem cell-based cartilage repair in osteoarthritis, addressing the chronic inflammation that drives joint aging.

💊 NEW CURES & APPROVALS

DASATINIB — SENOLYTIC INTEREST (PHYRAGO, HANDA THERAPEUTICS)

  • openFDA records a supplemental approval (SUPPL AP) for PHYRAGO (dasatinib), sponsored by Handa Therapeutics, under NDA216099.
  • Dasatinib is a tyrosine kinase inhibitor that has gained significant longevity-research attention as a senolytic agent — clearing senescent cells — in combination with quercetin, though current FDA-approved indications are oncological.
  • Bristol Myers Squibb's SPRYCEL (dasatinib, NDA021986) also received a supplemental approval in the same period.

PEMBROLIZUMAB — KEYTRUDA AND KEYTRUDA QLEX (MERCK SHARP DOHME)

  • Merck Sharp Dohme received a supplemental approval for KEYTRUDA (pembrolizumab, BLA125514), the PD-1 immune checkpoint inhibitor with broad oncology indications.
  • Merck also received a supplemental approval for KEYTRUDA QLEX (BLA761467), a co-formulation of pembrolizumab with berahyaluronidase alfa-pmph, enabling subcutaneous administration of what was previously an IV-only therapy.

SECUKINUMAB — COSENTYX (NOVARTIS PHARMACEUTICALS CORP)

  • Novartis received a supplemental approval for COSENTYX (secukinumab, BLA761349), an IL-17A inhibitor used in psoriasis, psoriatic arthritis, and ankylosing spondylitis.

UPADACITINIB — AUROBINDO PHARMA

  • Aurobindo Pharma received an original approval (ORIG AP) for a generic upadacitinib (ANDA218866), a JAK1-selective inhibitor used in rheumatoid arthritis, atopic dermatitis, and Crohn's disease.

TROFINETIDE — DAYBUE STIX (ACADIA PHARMACEUTICALS)

  • ACADIA Pharmaceuticals received a supplemental approval for DAYBUE STIX (trofinetide, NDA219884), a synthetic analog of the amino-terminal tripeptide of IGF-1 indicated for Rett syndrome.

IMATINIB MESYLATE — IMKELDI (SHORLA ONCOLOGY)

  • Shorla Oncology received a supplemental approval for IMKELDI (imatinib mesylate, NDA219097), a BCR-ABL tyrosine kinase inhibitor for CML and other indications.

CEVIMELINE — EVOXAC (COSETTE PHARMACEUTICALS NC)

  • Cosette Pharmaceuticals received an original approval for EVOXAC (cevimeline hydrochloride, NDA221183), a muscarinic agonist used for dry mouth in Sjogren's syndrome.

🧪 CLINICAL TRIALS

ROBOT-ASSISTED LONGEVITY EXERCISE FOR OLDER VETERANS

  • A newly registered ClinicalTrials.gov study (NCT07885813) is deploying a robotic system in a skilled nursing facility to deliver longitudinal combined physical and cognitive exercise interventions in older veterans, using a repeated baseline-intervention design to detect functional changes over time.
  • The protocol moves beyond prior short-term robotic exercise studies, emphasizing sustained multi-domain engagement — a design particularly relevant to slowing functional decline in aging populations.

TECAR THERAPY FOR KNEE OSTEOARTHRITIS IN ELDERLY MEN

  • Trial NCT07633795 is evaluating TECAR (capacitive and resistive electric transfer) therapy combined with traditional physiotherapy for pain, balance, and quality of life outcomes in elderly men with knee osteoarthritis.
  • Balance and pain are primary endpoints, addressing two major drivers of fall risk and functional aging in older adults.

PERFUSION-GUIDED BLOOD PRESSURE MANAGEMENT IN ELDERLY SEPTIC SHOCK

  • Trial NCT07887854 is a single-center randomized crossover physiological study in ICU patients aged 65 or older with septic shock, sequentially titrating mean arterial pressure (MAP) to three target ranges (including 60-65 mmHg) guided by perfusion efficiency measures.
  • The study addresses the clinical question of whether lower MAP targets are safe in elderly septic patients, which has direct implications for reducing vasopressor-related organ stress in aging physiology.

AI PRECISION NUTRITION FOR CHRONIC KIDNEY DISEASE

  • Trial NCT07829991 is testing a smartphone-based AI dietary image recognition system called CKDCare for patients with chronic kidney disease, assessing both usability and whether the system measurably changes dietary behavior — relevant to metabolic longevity in CKD populations.

[212Pb] TARGETED ALPHA THERAPY IN SMALL CELL LUNG CANCER

  • Trial NCT07278479 is evaluating [212Pb]Pb-DOTAM-MAM279 (also called [212Pb]Pb-MP0712), a lead-212 targeted alpha radiotherapy agent directed at DLL3-expressing tumors, in patients aged 18 and older with small cell lung cancer and other neuroendocrine cancers.
  • The study assesses safety, tolerability, dosimetry, and preliminary efficacy of this novel radiopharmaceutical approach.

B7-H3 CAR-T THERAPY FOR SMALL CELL LUNG CANCER

  • Trial NCT07509034 at a U.S. center is testing autologous B7-H3 chimeric antigen receptor (CAR) T-cells in previously treated extensive-stage small cell lung cancer and extrapulmonary neuroendocrine cancer, targeting B7-H3, a protein overexpressed on these highly lethal tumor types.

📢 PUBLIC HEALTH

LISTERIA OUTBREAK — PREPARED MEALS ONGOING

  • As of late October 2026 (updated 30 October), CDC continues to report new illnesses despite product recalls and urges consumers to check refrigerators and freezers for recalled prepared meal products and discard them immediately.
  • Earlier expansions of this Listeria outbreak added 3 additional illnesses and 1 additional death, with multiple prepared food brands implicated.

SALMONELLA — MULTIPLE ACTIVE OUTBREAKS

  • CDC is tracking a Salmonella outbreak linked to jalapeños reported across multiple states as of August 2026.
  • A separate Salmonella outbreak linked to alfalfa sprouts is ongoing, also involving E. coli co-contamination from the same recalled product.
  • An extensively drug-resistant Salmonella strain traced to moringa leaf powder capsules has resulted in hospitalizations; the moringa leaf Salmonella signal has accumulated across multiple outbreaks since late 2025.

ANIMAL RABIES ACTIVITY RISING

  • CDC issued a statement on 10 September 2026 flagging a notable increase in animal rabies activity and associated human exposure events across the United States, urging the public to avoid contact with wild and unfamiliar domestic animals and to seek post-exposure prophylaxis promptly after any potential exposure.

DRUG-RESISTANT BACTERIA SURGE

  • A CDC report released in September 2025 documented a dramatic increase in dangerous drug-resistant bacteria in U.S. healthcare settings, underscoring the continued threat of antimicrobial resistance to patient safety nationwide.

U.S. WHO WITHDRAWAL COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on 22 January 2026; WHO expressed that the withdrawal "makes both the United States and the world less safe."
  • The departure affects U.S. participation in international disease outbreak information-sharing frameworks at a time when multiple simultaneous global outbreaks are active.

BIOMED PULSE is an informational summary compiled from official public sources. Nothing here constitutes medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. Pneumonia of undetermined etiology - the Russian Federation — WHO Disease Outbreak News
  8. Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. CDC Provides Update on Hantavirus Outbreak Linked to M/V Hondi… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261022-02-v113 · 2026-10-22 02:01 UTC · pulse.uzylab.com